Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 15Thoracic 4Head & Neck 4Genitourinary 4Dermatologic 3Gynecologic 2Breast 1

Conditions

Melanoma 300Carcinoma, Non-Small-Cell Lung 80Squamous Cell Carcinoma of Head and Neck 59Carcinoma, Renal Cell 58Neoplasms 40Neoplasm Metastasis 36Colorectal Neoplasms 36Stomach Neoplasms 29Carcinoma, Merkel Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 28Carcinoma, Transitional Cell 27Uterine Cervical Neoplasms 24Skin Neoplasms 24Head and Neck Neoplasms 24Lung Neoplasms 22Breast Neoplasms 21Carcinoma, Hepatocellular 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 18Pancreatic Neoplasms 16Uveal Melanoma 14Small Cell Lung Carcinoma 14Sarcoma 14Urinary Bladder Neoplasms 12Lymphoma 11Kidney Neoplasms 11Endometrial Neoplasms 11Brain Neoplasms 11Prostatic Neoplasms 10

Interventions

pembrolizumab 3Nivolumab 2tislelizumab 1spartalizumab 1obinutuzumab 1naptumomab estafenatox 1durvalumab 1Rosiglitazone 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × pembrolizumab × Dermatologic × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT07223424 2026-04-16

PSI-Immune

University of Pittsburgh

Phase 2 Recruiting
880 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03809624 2024-10-23

PDL1x41BB

Inhibrx Biosciences, Inc

Phase 1 Terminated
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Oropharyngeal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡